Revolution Medicines (RVMD) Total Non-Current Liabilities (2019 - 2026)

Revolution Medicines has reported Total Non-Current Liabilities for 8 years, with the latest figure at $1.5 billion in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 175.01% year-over-year to $1.5 billion in Q2 2026; TTM through Jun 2026 was $1.5 billion, a 175.01% increase from a year earlier, with the FY2025 full-year figure at $704.7 million, up 143.07% from the prior year.
• Total Non-Current Liabilities was $1.5 billion for Q2 2026 at Revolution Medicines, up from $719.5 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $1.5 billion in Q2 2026, with the low at $119.3 million in Q1 2023.
• Average Total Non-Current Liabilities over 5 years is $359.3 million, with a median of $191.1 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities decreased 8.31% in 2023, then surged 234.7% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $126.4 million in 2022, then soared by 81.11% to $229.0 million in 2023, then increased by 26.6% to $289.9 million in 2024, then surged by 143.07% to $704.7 million in 2025, then soared by 117.38% to $1.5 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $1.5 billion (Q2 2026), $719.5 million (Q1 2026), and $704.7 million (Q4 2025), per Business Quant data.